Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients

Respiratory Research

Rex C Yung¹  Huiping Li²  Xia Zhang²  Yuxuan Zhang²  Yifan He²  Li Shen²  Shanshan Du²  Yang Hu²  Xianqiu Chen²  Yuan Zhang² 

[1] Department of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 21205, Baltimore, MD, USA;Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China

关键词: Serum Amyloid A;    Biomarker;    Proteomics;    Diagnosis;    Sarcoidosis;   

Others  :  796531
DOI  :  10.1186/1465-9921-14-18

 received in 2012-10-18, accepted in 2013-02-07,  发布年份 2013

【 摘 要 】

Background

The diagnosis of sarcoidosis is still a significant challenge in China because of the need to exclude other diseases including granulomatous infections and malignancies that may be clinically and radiographically similar. The specific aim of the study is to search for serum protein biomarkers of sarcoidosis and to validate their clinical usefulness in differential diagnosis.

Methods

Serum samples were collected from patients with sarcoidosis (n = 37), and compared to those from patients with tuberculosis (n = 20), other pulmonary diseases (n = 20), and healthy volunteers (n = 20) for determination of sarcoidosis-specific or -associated protein expression profiles. The first part of this study focused on proteomic analysis of serum from patients with sarcoidosis to identify a pattern of peptides capable of differentiating the studied populations using the ClinProt profiling technology based on mass spectrometry. Enzyme Linked Immunosorbent Assay (ELISA) was then used to verify corresponding elevation of the serum protein concentration of the potential biomarkers in the same patients sets. Receiver operating characteristic curve (ROC) analyses was performed to determine the optimal cutoff value for diagnosis. Immunohistochemistry was carried out to further confirm the protein expression patterns of the biomarkers in lung tissue.

Results

An unique protein peak of M/Z 3,210 Daltons (Da) was found to be differentially expressed between the sarcoidosis and control groups and was identified as the N-terminal peptide of 29 amino acids (94-122) of serum amyloid A (SAA). ELISA confirmed that the serum SAA level was significantly higher in the sarcoidosis group than that of the other 3 control groups (p < 0.05). The cutoff for serum SAA concentration determined by ROC analysis was 101.98 ng/ml, with the sensitivity and specificity of 96.3% and 52.5%, respectively. Immunohistochemical staining showed that the SAA depositions in lung tissue of the sarcoidosis patients were also significantly more intense than in non-sarcoid lung tissue (p < 0.05).

Conclusion

This is the first study to investigate serum protein markers in Chinese subjects with sarcoidosis. This study shows that the serum SAA expression profiles were different between the sarcoidosis and non-sarcoidosis groups. SAA may be a potential serum biomarker for ruling-out the diagnosis of sarcoidosis in Chinese subjects.

【 授权许可】

   
2013 Zhang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 2007, 357(21):2153.
• [2]Baughman RP, Culver DA, Judson MA: A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011, 183(5):573-81.
• [3]Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16(2):149-173.
• [4]Zhou Y, Li HP, Li QH, Zheng H, Zhang RX, Chen G, Baughman RP: Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of Mycobacterium tuberculosis. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25(2):93-99.
• [5]Li QH, Li HP, Shen YP, Zhao L, Shen L, Zhang Y, Jiang DH, Baughman RP: A Multi-parameter Scoring System for Distinguishing Sarcoidosis from Sputum Negative Tuberculosis. Sarcoidosis Vasc Diffuse Lung Dis 2012, 29(1):11-18.
• [6]Bargagli A, Mazzi P, Rottoli : Markers of inflammation in sarcoidosis: blood, urine, bal, sputum, and exhaled gas. Clin Chest Med 2008, 29(3):445-458.
• [7]Kruit A, Grutters JC, Gerritsen WB, Kos S, Wodzig WK, van den Bosch JM, Ruven HJ: ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007, 101(3):510-515.
• [8]Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, Higaki J: Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010, 137(6):1391-7.
• [9]Cravatt BF, Simon GM, Yates JR 3rd: The biological impact of mass-spectrometry-based proteomics. Nature 2007, 450(7172):991-1000.
• [10]Shevchenko VE, Arnotskaya NE, Zaridze DG: Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom 2010, 16(4):539-549.
• [11]Hartwig S, Kotzka J, Müller H, Müller-Wieland D, Eckel J, Lehr S: Enhancing mass spectrometry based serum profiling by a combination of free flow electrophoresis and ClinProt. Arch Physiol Biochem 2009, 115(5):259-266.
• [12]Malle E, De Beer FC: Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996, 26(6):427-435.
• [13]Rubinstein I, Knecht A, de Beer FC, Baum GL, Pras M: Serum amyloid-A protein concentrations in sarcoidosis. Isr J Med Sci 1989, 25(8):461-462.
• [14]Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, Groshong SD, Zhang Y, Tuder RM, Moller DR: Serum Amyloid A Regulates Granulomatous Inflammation in Sarcoidosis through Toll-like Receptor-2. Am J Respir Crit Care Med 2010, 181(4):360-373.
• [15]Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P: Analysis of serum amyloid A in sarcoidosis patients. Respir Med 2011, 105(5):775-80.
• [16]Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, Wark PA, Hutchinson A, Irving LB, Levy BD, Anderson GP: Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2012, 109(3):935-40.
• [17]Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW, Cho JY: Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011, 10(3):1383-95.
• [18]Salazar A, Pintó X, Mañá J: SAA and HDL-cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 2001, 31(12):1070-1077.
• [19]Salazar A, Maña J, Fiol C, Hurtado I, Argimon JM, Pujol R, Pinto X: Influence of SAA on decrease of HDL-cholesterol in active sarcoidosis. Atherosclerosis 2000, 152(2):497-502.
• [20]Yamada T: Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999, 37(4):381-388.
• [21]Lenz AG, Meyer B, Costabel U, Maier K: Bronchoalveolar lavage fluid proteins in human lung disease: Analysis by two-dimensional electrophoresis. Electrophoresis 1993, 14(3):242-244.
• [22]Wattiez R, Hermans C, Cruyt C, Bernard A, Falmagne P: Human bronchalveolar lavage fluid protein two-dimensional database: Study of interstitial lung diseases. Electrophoresis 2000, 21(13):2703-2712.
• [23]Magi B, Bini L, Perari MG, Fossi A, Sanchez JC, Hochstrasser D, Paesano S, Raggiaschi R, Santucci A, Pallini V, Rottoli P: Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: A two-dimensional electrophoretic study. Electrophoresis 2002, 23(19):3434-3444.
• [24]Sabounchi-Schütt F, Aström J, Hellman U, Eklund A, Grunewald J: Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: proteomics approach. Eur Respir J 2003, 21(3):414-420.
• [25]Rottoli P, Magi B, Cianti R, Bargagli E, Vagaggini C, Nikiforakis N, Pallini V, Bini L: Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005, 5(10):2612-2618.
• [26]Kriegova E, Melle C, Kolek V, Hutyrova B, Mrazek F, Bleul A, du Bois RM, von Eggeling F, Petrek M: Protein Profiles of Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis. Am J Resp Crit Care 2006, 173(10):1145-1154.
• [27]Bons JA, Drent M, Bouwman FG, Mariman EC, van Dieijen-Visser MP, Wodzig WK: Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respir Med 2007, 101(8):1687-1695.
• [28]Gianazza E, Mainini V, Castoldi G, Chinello C, Zerbini G, Bianchi C, Galbusera C, Stella A, Mauri G, Zoppis I, Magni F, Kienle MG: Different expression of fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy. J Proteomics 2010, 73(3):593-601.